NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, OR JAPAN OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
New agreement enables analysis of anonymised patient data using clinical artificial intelligence technology to accelerate medical research, help find new treatments and improve patient care.
Oxford, UK; 1st August 2018: Sensyne Health Limited (the “Company”), formerly Drayson Health, a British clinical AI technology company, announces today that it has signed a Strategic Research Agreement (SRA) with Chelsea and Westminster Hospital NHS Foundation Trust. The agreement will allow Sensyne Health to analyse anonymised patient data using clinical artificial intelligence (Clinical AI) technology*. The agreement also includes a new research collaboration between the parties in digital health and biomedical research. The purpose of the research is to derive new insights that will improve the care of the Trust’s patients and help to find new treatments.
Chelsea and Westminster Hospital NHS Foundation Trust will receive a £5 million equity stake in Sensyne Health and will also benefit from royalties that arise from any discoveries. The royalties the Trust receives will be reinvested back into the NHS which can fund further research and help deliver higher quality patient care at lower cost.
Research will be undertaken to the highest standards of information governance and data security in accordance with the Caldicott Principles and data protection legislation.
LESLEY WATTS, CEO, CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST, SAID:
“We are always seeking ways to improve the care we deliver to our patients, whilst ensuring patient information is safe and secure. This exciting and innovative partnership offers the potential to unlock new digital health treatments, allowing us to continue to deliver the very highest quality of care to our patients now and in the future.”
LORD (PAUL) DRAYSON, CEO OF SENSYNE HEALTH, COMMENTED:
“We are delighted that the Chelsea and Westminster NHS Foundation Trust, a leading acute Trust in the heart of London, has joined our research partnership in clinical AI alongside South Warwickshire and Oxford University Hospitals NHS Foundation Trusts. Together, we aim to make new discoveries that will improve care for patients, accelerate medical research and provide a return back into the NHS.”
For more information please contact:
Notes for editors:
The new agreement builds on an existing relationship with Chelsea and Westminster Hospital NHS Foundation Trust, formed in September 2017, when the parties announced a global first, piloting Sensyne Health’s wireless environmental sensors in intensive care units at Chelsea and Westminster Hospital.
ABOUT SENSYNE HEALTH
Sensyne Health is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with the Caldicott Principles, UK data protection law and applicable regulatory guidance.
Sensyne Health, which recently changed its name from Drayson Health, is based in the Big Data Institute at the University of Oxford's Old Road Campus.
For more information, please visit: www.sensynehealth.com
ABOUT CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST
It is one of the best performing Trusts in the country. It employees around 6,000 staff and has recently been rated as ‘Good’ by the Care Quality Commission (CQC), and Outstanding for use of resources by NHS Improvement.
The Trust operates two hospitals, one in central London, the Chelsea and Westminster hospital, and one in Isleworth West London, the West Middlesex University Hospital.
WHAT IS ‘CLINICAL AI’?
Clinical AI is a highly specialised field of AI which uses machine learning algorithms, including deep learning in tandem with human clinical expertise and big datasets with which to train the algorithms. Clinical AI is particularly concerned with the analysis of data acquired during routine clinical care of patients, in order to derive clinically-useful results such as to improve patient outcomes and to discover new insights about the use of pharmaceutical compounds to treat patients.
This announcement does not constitute or form part of an offer to sell or issue or a solicitation of an offer to subscribe for or buy any securities nor should it be relied upon in connection with any contract or commitment whatsoever.
These materials are not an offer of securities for sale in the United States. The securities to which these materials relate have not been registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States.